-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Marcia F. T. Rupnow, PhD

Articles by Marcia F. T. Rupnow, PhD

Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

ByRobert A. Bailey, MD,Ujjwala Vijapurkar, PhD,Gary E. Meininger, MD,Marcia F. T. Rupnow, PhD,Lawrence Blonde, MD

December 16th 2014

Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus

ByVarun U. Ektare, BPharm, MPH,Janice M. S. Lopez, PharmD, MPH,Silas C. Martin, MS,Dipen A. Patel, BPharm, PhD,Marcia F. T. Rupnow, PhD,Marc F. Botteman, MSc, MA

October 26th 2014

Participating Faculty: Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus

ByVarun U. Ektare, BPharm, MPH,Janice M. S. Lopez, PharmD, MPH,Silas C. Martin, MS,Dipen A. Patel, BPharm, PhD,Marcia F. T. Rupnow, PhD,Marc F. Botteman, MSc, MA

October 26th 2014

Attainment of Diabetes-Related Quality Measures With Canagliflozin Versus Sitagliptin

ByRobert A. Bailey, MD,C. V. Damaraju, PhD,Silas C. Martin, MS,Gary E. Meininger, MD,Marcia F. T. Rupnow, PhD,Lawrence Blonde, MD

January 25th 2014

Latest Updated Articles

Participating Faculty: Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus
October 26th 2014
Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus
October 26th 2014
Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials
December 16th 2014
Attainment of Diabetes-Related Quality Measures With Canagliflozin Versus Sitagliptin
January 25th 2014

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS